Loading
Life sciences · Journal article
Вестник Волгоградского Государственного Медицинского Университета · October 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Bladder cancer is one of the most common malignant neoplasms, which are among the top ten in the structure of oncological pathology in many countries of the world. The increasing incidence of bladder cancer in the Russian Federation determines the need to use all the most effective medical technologies to reduce this socio-economic burden. A feature of the disease is the steadily recurrent nature of the course. Intravesical BCG therapy is one of the tools capable of controlling the frequency and timing of disease return. This area of antitumor pharmacotherapy becomes possible with the provision of the necessary equipment, compliance with the conditions for intravesical instillation with BCG vaccine, staff training, strict selection and preparation of patients. Purpose: Analysis of the experience in implementing intravesical BCG therapy in the treatment of non-muscle-invasive bladder cancer at a regional oncology clinic. Materials and methods: The study is based on an appeal to the regulations governing the procedure for BCG therapy in a regional oncological dispensary, in comparison with the current Clinical recommendations of the Russian Ministry of Health for the treatment of bladder cancer and the experience of other medical organizations. In accordance with the requirements of GOST R 57525-2017, a prospective clinical and economic follow-up was conducted with an analysis of the "cost of the disease" at the stage of intravesical BCG therapy. Results and discussion: The study reflects in detail the qualitative changes in the provision of medical care to patients with bladder cancer as a result of the introduction of intravesical immunotherapy. The clinical effectiveness of the organized line of activity is justified due to numerous scientific data confirming its effectiveness. According to the economic efficiency analysis, the financial feasibility of BCG therapy, in particular with the use of a domestically produced vaccine, is obvious. The results of the analysis are confirmed by the published research experience of specialists in the field of oncourology. Conclusion: The introduction of intravesical BCG therapy significantly improves the quality of specialized medical care for patients with bladder cancer, is clinically effective and economically justified. A valuable aspect of the organization of this area of medical care is the absence of the need for significant financial investments in the current activities of the institution. The practical application of the BCG vaccine in the care of oncourological patients complies with the Clinical recommendations of the Russian Ministry of Health and modern international standards for the treatment of bladder cancer.